$KPTI positive results from phase 2/3

Micro cap Karyopharm Therapeutics (KPTI) announced positive results from its Phase 2/3 clinical trial, SEAL, assessing selinexor ((KPT-330)) in patients with previously treated, advanced, unresectable, dedifferentiated liposarcoma.

Read the full brief in our Daily Pharma Scoop at SeekingAlpha Marketplace.